Pacira Biosciences Inc

PCRX

21.000USD

+0.640+3.14%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Pacira Biosciences Inc's Score

Industry at a Glance

Industry Ranking

35 / 159

Overall Ranking

100 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Pacira Biosciences Inc Highlights

StrengthsRisks

Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 45.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 49.20M shares, decreasing 27.91% quarter-over-quarter.

Held by HOTCHKIS & WILEY

Star Investor HOTCHKIS & WILEY holds 627.00 shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

29.714

Target Price

+43.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Pacira Biosciences Inc is 8.78, ranking 37 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 179.52M, representing a year-over-year increase of 6.49%, while its net profit experienced a year-over-year increase of 103.79%.

Score

Industry at a Glance

Previous score

8.78

Change

0



Financials

7.01

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.34

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.55

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Pacira Biosciences Inc is 8.28, ranking 23 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 45.18, which is 417.46% below the recent high of 233.78 and 935.64% above the recent low of -377.53.

Score

Industry at a Glance

Previous score

8.28

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 35/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Pacira Biosciences Inc is 7.14, ranking 116 out of 159 in the Pharmaceuticals industry. The average price target is 28.00, with a high of 38.00 and a low of 23.00.

Score

Industry at a Glance

Previous score

7.14

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Pacira Biosciences Inc is 6.92, ranking 96 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 24.34 and the support level at 18.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Pacira Biosciences Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 119.71%, representing a quarter-over-quarter decrease of 1.17%. The largest institutional shareholder is The Vanguard, holding a total of 4.76M shares, representing 11.59% of shares outstanding, with 3.39% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

6.38M

-4.63%

The Vanguard Group, Inc.

Star Investors

5.15M

-3.89%

DOMA Perpetual Capital Management, LLC

2.94M

--

Dimensional Fund Advisors, L.P.

2.16M

+0.55%

Renaissance Technologies LLC

Star Investors

2.14M

--

D. E. Shaw & Co., L.P.

1.94M

-13.81%

State Street Investment Management (US)

1.90M

-2.57%

Balyasny Asset Management LP

1.89M

-11.53%

American Century Investment Management, Inc.

1.38M

+16.57%

Geode Capital Management, L.L.C.

1.22M

+6.36%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pacira Biosciences Inc is 6.66, ranking 51 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Pacira Biosciences Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Pacira Biosciences Inc

PCRX

7.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment